- Home
- STCN vs ALVR Comparison
STCN vs ALVR Comparison
Compare STCN & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STCN
- ALVR
- Stock Information
- Founded
- STCN 1986
- ALVR 2013
- Country
- STCN United States
- ALVR United States
- Employees
- STCN N/A
- ALVR N/A
- Industry
- STCN Advertising
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STCN Consumer Discretionary
- ALVR Health Care
- Exchange
- STCN Nasdaq
- ALVR Nasdaq
- Market Cap
- STCN 63.4M
- ALVR 87.7M
- IPO Year
- STCN 1994
- ALVR 2020
- Fundamental
- Price
- STCN $10.40
- ALVR $0.90
- Analyst Decision
- STCN
- ALVR Sell
- Analyst Count
- STCN 0
- ALVR 5
- Target Price
- STCN N/A
- ALVR $1.00
- AVG Volume (30 Days)
- STCN 11.9K
- ALVR 155.6K
- Earning Date
- STCN 12-12-2024
- ALVR 11-04-2024
- Dividend Yield
- STCN N/A
- ALVR N/A
- EPS Growth
- STCN 203.29
- ALVR N/A
- EPS
- STCN 3.17
- ALVR N/A
- Revenue
- STCN $169,044,000.00
- ALVR N/A
- Revenue This Year
- STCN N/A
- ALVR N/A
- Revenue Next Year
- STCN N/A
- ALVR N/A
- P/E Ratio
- STCN $3.19
- ALVR N/A
- Revenue Growth
- STCN N/A
- ALVR N/A
- 52 Week Low
- STCN $7.36
- ALVR $0.58
- 52 Week High
- STCN $13.00
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- STCN 57.19
- ALVR 69.10
- Support Level
- STCN $9.90
- ALVR $0.74
- Resistance Level
- STCN $10.29
- ALVR $0.91
- Average True Range (ATR)
- STCN 0.39
- ALVR 0.06
- MACD
- STCN 0.11
- ALVR 0.01
- Stochastic Oscillator
- STCN 100.00
- ALVR 94.50
About STCN Steel Connect Inc.
Steel Connect Inc is a diversified holding company. The company's operating segment include Direct Marketing and Supply Chain. It generates maximum revenue from the Direct Marketing segment. Geographically, it derives a majority of revenue from the United States and also has a presence in China; Netherlands, and others. The company serves clients in various industries including consumer electronics, communications, computing, software, storage, and retail industries.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.